Milwaukee Health Services taps new corporate communications specialist
MILWAUKEE, Wis. Milwaukee Health Services, which owns and operates a retail-based convenient care clinic here, has hired Clarene Mitchell as corporate communications specialist.
In her new role, Mitchell’s duties will include advancing the organization’s public image, facilitating business and government partnerships, fundraising strategy efforts and special projects.
An initial area of concentration will focus on increasing the public image and utilization of MHSI’s Convenient Care Clinic that operates in the Midtown Piggly Wiggly supermarket. MHSI opened the clinic in October 2009 in partnership with Managed Health Services. The clinic, which is owned and operated by MHSI, was the first retail based clinic to be opened by a Federally Qualified Health Center on a national basis, the company stated.
Mitchell most recently worked with VITAS Innovative Hospice Care. Her professional history includes managing programs and public relations interests for Black Health Coalition of Wisconsin. Prior to that she was a health communications officer for the Milwaukee Health Department, the health and education liaison for Mayor John O. Norquist, in addition to other roles with such organizations as Sojourner Truth House, American Lung Association, Lisbon Avenue Neighborhood Development and the Milwaukee Urban League.
Mission launches Uribel
SAN ANTONIO Drug maker Mission Pharmacal has launched a treatment for urinary tract infections.
Mission announced the launch of Uribel (methenamine, sodium phosphate monobasic, phenyl salicylate, methylene blue and hyoscyamine sulfave) capsules, used to relieve local discomfort and inflammation associated with lower urinary tract infections, interstitial cystitis, painful bladder syndrome and urinary tract procedures.
Mission will handle distribution and marketing of Uribel for Star Pharmaceuticals, while an unnamed third party company will manufacture the drug.
“Uribel is an important expansion of our urology and women’s health product portfolio, and we’re excited to be partnering with Star Pharmaceuticals to bring this product to patients,” Mission president of commercial operations Terry Herring said. “Uribel provides three complementary ways to treat uncomfortable urinary tract conditions – an analgesic to relieve pain and burning, an antispasmodic to reduce urinary urgency and antiseptic that inhibits the growth of bacteria.”
Genzyme, Isis announce study results for mipomersen
CAMBRIDGE, Mass. Biotech company Genzyme and Isis Pharmaceuticals have finished late-stage clinical trials of a cholesterol-lowering drug, the two companies said.
Genzyme and Isis announced results of two phase 3 studies of the drug mipomersen in patients who have high cholesterol levels while taking high doses of cholesterol-lowering medications. The studies were conducted in North America, Europe and South Africa.
In one study of patients with severe hypercholesterolemia, mipomersen reduced “bad” LDL cholesterol by 36%, compared with 13% among those taking placebo; in the other study of patients with high cholesterol at high risk of cardiovascular disease, the drug reduced LDL cholesterol by 37%, compared with 5% among those taking placebo.